Arpeggio is selected as a finalist for the Rising Star of the Year Award by the Colorado BioScience Association.
Arpeggio Co-Founders Laura Norris and Joey Azofeifa are recognized as emerging business leaders in Boulder Valley.
We presented two posters at AACR describing how high-throughput transcriptomics is helping to identify novel GPX4 inhibitors.
In collaboration with Forma Therapeutics, Arpeggio uses their transcriptional platform to uncover novel mechanisms of CBP inhibitors.
We have partnered with Builders VC, and many returning investors, to develop our pipeline of transcriptomic medicine.
Arpeggio featured in a great write up by Paul Schloesser on how we're building our drug pipeline and discovery platform.
A feature on Arpeggio and our mission to bring new medicine to patients with cancer and rare disease.
Arpeggio will be a presenting company as well as forming connections through BIO one-on-one partnering throughout the week.
We were selected to pitch at Destination Startup Ventures 2021, a showcase featuring the best companies from across the Rocky Mountain Region.
Arpeggio was featured in the Colorado BioScience Association’s annual publication: “Arpeggio Biosciences: Fusing Big Data With Molecular Biology”
Joey was a featured speaker, presenting: "Drugging Oncogenic Transcription Factors with Enhancer Activity Screen"
Arpeggio announces: "Arpeggio Bio raises $3.2 million in seed funding and CEO named to the 2020 Forbes 30 Under 30 list in healthcare"
Forma Therapeutics announces partnership with Arpeggio: “Celgene-partnered Forma teams with Arpeggio to understand drug-target interactions”
Have questions? Interested in partnering with Arpeggio? Let us know.
